Eleonora Riccio

11PUBLICATIONS
27CO-AUTHORS
Transplantation immunologyNutrigenomics and personalised nutritionNaturopathyCancer therapy (excl. chemotherapy and radiation therapy)Cell development, proliferation and death
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 25, 2026
Feasibility and safety of pegunigalsidase alfa infusion during hemodialysis: first case report in a Fabry patient with kidney failure.

|May 20, 2026
DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease.

|Aug 12, 2025
Real-World Migalastat Use in Fabry Disease: Comparative Insights From the Pisani and Hughes Studies.

Eleonora Riccio, Antonio Pisani

|Nov 14, 2022
New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.

Eleonora Riccio, Antonio Pisani

|Mar 23, 2021
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.

Eleonora Riccio, Mario Zanfardino, Monica Franzese

|Jul 11, 2020
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.

Eleonora Riccio, Mario Zanfardino, Lucia Ferreri

Pageof 2

Frequent Collaborators

2 joint publications

Massimo Sabbatini

2 joint publications

Gaia Peluso

2 joint publications

Paola Incollingo

2 joint publications

Nicola Carlomagno